Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma

Launched by ST. JUDE CHILDREN'S RESEARCH HOSPITAL · Dec 20, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to diagnose a condition called cardiac autonomic dysfunction (AD) in survivors of childhood cancers, specifically those who had acute lymphoblastic leukemia or Hodgkin's lymphoma. The researchers want to see if they can accurately identify this condition using remote technology, like a biosensor device, instead of needing participants to come in for a physical appointment. This could help doctors catch AD earlier and make it easier to study how it affects patients.

To be eligible for the study, participants need to be at least 18 years old and have survived either acute lymphoblastic leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. They should not be taking certain heart medications called beta-blockers. Participants will complete some assessments remotely, which will help researchers compare these new methods to traditional in-person tests. Overall, this trial aims to improve how we identify heart issues in young cancer survivors and potentially help them stay healthier in the long run.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) \>18 years of age.
• • Primary diagnosis of acute lymphoblastic leukemia (ALL), Hodgkin's Lymphoma (HL), or Non-Hodgkin's Lymphoma (Non-HL).
• • Not currently taking beta-blocker medication.
• Exclusion Criteria:
• • Individuals who cannot speak, read, and/or understand English.
• • Individuals who are unable to follow directions/instructions in order to complete the Ewing battery.
• • Individuals with acute heart failure (new or worsening signs and symptoms of heart failure, including a combination of the following: dyspnea, orthopnea, lower limb swelling, elevated jugular venous pressure, and pulmonary congestion).
• • Women who are currently pregnant.